Have your marketers entered Marketer of the Year 2017 yet?

Entrants so far have come from Shire, Bayer, AbbVie, Eisai Europe, Novartis, GSK, MSD, Lundbeck, HFA Healthcare Products, Sandoz and Bristol-Myers Squibb Pharmaceuticals among others. Don't miss out on this crucial opportunity to identify and benchmark talent within your organisation against others in the industry.

Read on PharmaTimes

EU nod for Chiesi’s COPD therapy

European regulators have green-lighted Chiesi’s new chronic obstructive pulmonary disease (COPD) maintenance therapy Trimbow.

Read on PharmaTimes

US, EU filings for Eisai’s lenvatinib in liver cancer

Eisai has filed its anticancer drug lenvatinib for liver cancer on both sides of the Atlantic as it seeks to expand the drug’s list of approved uses.

Read on PharmaTimes

Verona Pharma begins dosing RPL554 in Phase IIb COPD trial

Patients have begun receiving Verona Pharma’s experimental respiratory drug RPL554 in a Phase IIb trial assessing its potential as a maintenance therapy for chronic obstructive pulmonary disease (COPD).

Read on PharmaTimes

NICE backs Roche’s Gazyvaro for follicular lymphoma

The National Institute for Health and Care Excellence has issued final draft guidance recommending that use of Roche’s Gazyvaro to treat follicular lymphoma be funded for NHS use via the Cancer Drug Fund.

Read on PharmaTimes

1 2 3

Top of page

Industry News

Entrants so far have come from Shire, Bayer, AbbVie, Eisai Europe, Novartis, GSK, MSD, Lundbeck, HFA Healthcare Products, Sandoz and...
Read More >

More Stories

News

Recent launch of several new categories of compound which include the spirocyclic β-Lactams designed...
Read More >

More Stories

Latest Tweets

Follow Us